TWO · 3176.TWO
Medigen Biotechnology Corp.
NT$33.20NT$0.00 (0.0%)
Medigen Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 23.85% below the high.
Loading market information…
TWO · 6535.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Lumosa Therapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Lumosa Therapeutics Co., Ltd.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -NT$0.39. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lumosa Therapeutics Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 5, 2025 | -NT$0.63-31.25% vs estimate | NT$8.90M+77.92% vs estimate |
|---|
| Q4 2024 | Mar 3, 2025 | -NT$0.90-93.55% vs estimate | NT$14.00M0.0% vs estimate |
|---|
| Q3 2024 | Nov 11, 2024 | -NT$1.40-174.51% vs estimate | NT$6.37M-36.31% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$33.20NT$0.00 (0.0%)
Medigen Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 23.85% below the high.
NT$30.95NT$0.00 (0.0%)
Senhwa Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.46% below the high.
NT$32.00NT$0.00 (0.0%)
Energenesis Biomedical CO.,LTD.’s quoted price sits in the lower half of its reported 52-week range, 46.4% below the high.
NT$11.95NT$0.00 (0.0%)
TaiRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.62% below the high.
